KalVista Pharmaceuticals Touts EKTERLY Launch: Nearly $50M in Under 6 Months, 20% Patient Reach

KalVista Pharmaceuticals (NASDAQ: KALV) CEO Ben Palleiko told investors at Needham and Company's 25th Annual Healthcare Conference that the company has seen a strong early commercial launch for EKTERLY, which he described as the "first and only oral on-demand therapy for treatment of HAE attacks." Palleiko said the company launched EKTERLY immediately after FDA approval last